Australia Angiography Devices Market Analysis Industry Trends and Forecast to 2034: Segmented by (By Product Type, By Technology, By Procedure, By Application, By End User, By Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
Australia · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$161.1 MnPlaceholder estimate
Estimate 2025$173.6 Mn1.2% of the global market
Projected 2034$341.3 Mn 96.6%Adds $167.7 Mn over 9 forecast years
CAGR 2025–20347.8%Faster than 19% of 173 Medical Devices markets here
40 in AustraliaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 9 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The Australia Angiography Devices Market Executive Summary
Angiography devices are specific diagnostic imaging systems that are employed in the depiction of blood vessels and organs with the primary use of X-ray Image Experience. He explains how these devices help in conducting angiogram, which is the process of taking images of blood vessels through injecting contrast dye into the vessels to make any blockage or irregularity visible on television monitor. The systems can display fluoroscopic views in real time and are important in diagnostic and interventional cardiology.
It holds a strategic position in medical diagnosis through angiography devices such as Digital Subtraction Angiography (DSA), Computed Tomography Angiography (CTA), Magnetic Resonance Angiography (MRA), and ultrasound. These devices are essential especially for conditions affecting the blood vessels and the nervous system. Market, factors include technological trends like the use of artificial intelligence, minimally invasive procedures, rising incidences of cardiovascular diseases, and heightened life expectancy. North America currently adopts a large market share and followed by Europe and Asia-Pacific with a rapidly growing market. Major players are GE Healthcare and Siemens Healthineers. They include high costs and regulatory constraints.
Australia Angiography Devices market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
Australia Angiography Devices Market Dynamics
Market Growth Drivers
A growing incidence of cardiovascular diseases, especially among the aging population, has led to a higher number of diagnostic and interventional procedures involving angiography technology. This is mainly because of the progressive improvements in the technological innovations utilized in such devices, thus expanding their utilization in healthcare facilities. Further, the minimally invasive treatments, which provide more rapid recovery, are gaining popularity in the global market for drivers and angiography devices.
Opportunity
The angiography devices market also holds great potential for future growth in terms of entering markets that are currently in the development stage of their healthcare industry, and where the demand for angiography and other related technologies is rising rapidly. The integration of AI in angiography devices may improve diagnostic outcomes and allow for more patient-tailored therapies. Another opportunity is there existing a lucrative market in portable home-use devices for patients with chronic illnesses and those who cannot easily visit hospitals.
Market Restraints
High and increasing prices for the equipment and the procedures; the use of radiation during the procedures and their higher availability in developed regions. Lack of sound reimbursement policies and scarcity of skilled workforce also inhibit adoption of HIE. In the same manner, there are some challenges associated with this technology whereby some new products may take longer to gain approval from the authorities which may slow down production and distribution of new products.
Competitive Landscape for Angiography Devices Market in Australia
August 2024, Shimadzu Medical Systems USA introduced the Trinias angiography system at the SIR 2022 Annual Meeting. This system uses AI deep learning to enhance device visibility and reduce X-ray exposure by over 40% compared to previous models. It is the first angiography system to incorporate AI into its image processing engine.
October 2025, Abbott launched new vascular imaging platform in India. Unlike traditional imaging methods such as conventional angiography, the intravascular imaging software uses near- infrared light to provide high-definition, precise imaging from within blood vessels, allowing physicians to capture information from even the most complex patient anatomy.
September 2022, Siemens Healthineers launched angiography system, ARTIS icono in India. The new ARTIS icono systems adapt flexibly to the differing needs of cardiovascular interventions, interventional radiology, neuroradiology, and vascular interventions.
June 2022, Shimadzu Corporation announced the commencement of worldwide sales of the newest version of the company’s Trinias angiography system. Shimadzu Medical Systems USA introduced the new system at the SIR 2022 annual scientific meeting held June 11-16 in Boston, Massachusetts.
Mergers and Acquisitions
June 2024, Silk Road Medical, Inc., a leading minimally invasive medical device company for carotid artery procedures, announced today it has entered into a definitive agreement to be acquired by Boston Scientific Corporation, a global medical technology leader, for $27.50 in cash per share, representing an equity value of approximately $1.26 billion.
March 2024, Titan Medical Inc. announced that it has entered into a definitive amalgamation agreement dated March 17, 2024 with Conavi Medical Inc. to combine the companies in an all-stock transaction. The combined company will focus on continuing to commercialize Conavi’s Novasight Hybrid System designed to guide common minimally invasive coronary procedures.
November 2025, Johnson & Johnson MedTech Acquires Laminar, Inc. Innovative investigational device designed for Left Atrial Appendage Elimination (LAAX) to reduce the risk of stroke in patients with non-valvular atrial fibrillation.
Healthcare Policies and Regulatory Landscape for Angiography Devices Market in Australia
Angiography Devices in Australia: rules, payment and research
Medical devices must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied.[1] Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines.[2] ClinicalTrials.gov lists 40 studies on Angiography Devices that are recruiting, active or about to start in Australia.[3]
[3]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 9 Nov 2026.
Policy changes and Reimbursement scenario
Government initiatives across countries especially in north America such as low tax incentives and favourable policy environment also the recent ease in the regulatory frameworks in areas of Europe including Germany are also driving the advancements of angiography technologies. There has also been a shift toward less invasive treatments, which is also spurring adoption of these devices. Reimbursement policies, especially in North American region which most of its procedures are reimbursable by Medicare and private insurance companies are the primary drivers of the market. However, this variability in reimbursement rates across regions may affect the adoption of the technology especially in developing markets where health coverage and system are still being established.
8.2 Government Initiatives / Intervention programs
The angiography devices market can be segmented based on several criteria, including product type, technology, application, end user, and region. Here’s a detailed overview of the segmentation:
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: FDA 510(k) and PMA databases, 510(k) clearances and PMA approvals since 2015 for devices whose name has this market's words. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Angiography Devices right now, from free public sources.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
World Bank.
Fetched 9 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Public data, with sources
Angiography Devices in context
Australia compared
Health spending per person: 6,980 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 15 countries we cover in APAC.[1]
Doctors: 4.09 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 15 countries we cover in APAC.[2]
People aged 65 and over: 18.1% of people (2025). World: 10.4% of people (2025). 3rd highest of the 16 countries we cover in APAC.[3]
[1]World Bank Open Data, Health spending per person (US$ per person). Retrieved 15 Nov 2026.
How big is the Angiography Devices market in Australia?
Placeholder estimate: about $173.6 Mn in 2025, rising to about $341.3 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Angiography Devices market in Australia growing?
Placeholder estimate: about 7.8% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Angiography Devices market report cover?
The report splits the market by product type (Angiography Systems, Angiography Catheters, Angiography Contrast Media, Vascular Closure Devices (VCDs) and more), procedure (Coronary Angiography, Endovascular Angiography, Neuroangiography, Onco-angiography and more), application (Diagnostics, Therapeutics) and end user (Hospitals and Clinics, Diagnostic and Imaging Centres, Research Institutes).
Who are the key players in the Angiography Devices market?
Key players include GE Healthcare, Siemens Healthineers, Boston Scientific Corporation, Medtronic, Philips Healthcare and AngioDynamics, Inc., among 7 companies the report profiles.
What is driving the Angiography Devices market?
A growing incidence of cardiovascular diseases, especially among the aging population, has led to a higher number of diagnostic and interventional procedures involving angiography technology.
Who regulates Angiography Devices in Australia?
Medical devices must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied. Source: Therapeutic Goods Administration. Checked 14 Nov 2026.
How is healthcare paid for in Australia?
Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines. Source: Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.
How many clinical trials on Angiography Devices are running in Australia?
40 studies are recruiting, active or about to start in Australia, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 9 Nov 2026.
How much research is published on Angiography Devices?
PubMed lists 59,580 papers on Angiography Devices added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 9 Nov 2026.